Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
BI-905711 by Boehringer Ingelheim International for Metastatic Adenocarcinoma of The Pancreas: Likelihood of Approval
BI-905711 is under clinical development by Boehringer Ingelheim International and currently in Phase I for Metastatic Adenocarcinoma of The Pancreas....
BI-905711 by Boehringer Ingelheim International for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval
BI-905711 is under clinical development by Boehringer Ingelheim International and currently in Phase I for Pancreatic Ductal Adenocarcinoma. According to...
BI-905711 by Boehringer Ingelheim International for Gallbladder Cancer: Likelihood of Approval
BI-905711 is under clinical development by Boehringer Ingelheim International and currently in Phase I for Gallbladder Cancer. According to GlobalData,...
BI-905711 by Boehringer Ingelheim International for Bile Duct Cancer (Cholangiocarcinoma): Likelihood of Approval
BI-905711 is under clinical development by Boehringer Ingelheim International and currently in Phase I for Bile Duct Cancer (Cholangiocarcinoma). According...
BI-905711 by Boehringer Ingelheim International for Metastatic Colorectal Cancer: Likelihood of Approval
BI-905711 is under clinical development by Boehringer Ingelheim International and currently in Phase I for Metastatic Colorectal Cancer. According to...
BI-905711 by Boehringer Ingelheim International for Esophageal Cancer: Likelihood of Approval
BI-905711 is under clinical development by Boehringer Ingelheim International and currently in Phase I for Esophageal Cancer. According to GlobalData,...
BI-905711 by Boehringer Ingelheim International for Gastric Cancer: Likelihood of Approval
BI-905711 is under clinical development by Boehringer Ingelheim International and currently in Phase I for Gastric Cancer. According to GlobalData,...